Pharmacokinetic and 48 week Efficacy of Once-Daily vs Twice-Daily Dolutegravir among patients with Human Immunodeficiency virus/Tuberculosis coinfection receiving rifampicin based tuberculosis therapy: A Randomized control trial

Category Primary study
ConferenceAIDS 2022 - the 24th International AIDS Conference
Year 2022
This article has no abstract
Epistemonikos ID: 9457b439624f6eb3a3e9b47cbccabe56ab689dc3
First added on: Jan 10, 2026